K 01-162

K 01-162 (K162) inhibits the fibril formation of A β peptides and eliminates their neurotoxicity. K 01-162 binds with A β 42 peptide with an EC 50 value of 80 nM. K 01-162 binds directly to AβO with a K D value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease. In Vitro K 01-162 (1 μM; 24 h) reduces the level of intracellular AβO. K 01-162 (0.78-50 μM; 5 min) blocks the synaptic binding activity of AβO in mouse hippocampal neurons. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MC65 cell line Concentration: 1 μM Incubation Time: 24 hours Result: Reduced the levels of SDS-stable Aβ trimer and larger aggregates. In Vivo K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 5xFAD mice with cerebral Aβ amyloidosisDosage: 100 μM Administration: Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks Result: Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to 50% of the mock-treated level.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet